Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vestipitant vs Ondansetron for Breakthrough PONV
NCT01507194Phase 2Completed
- Sponsor
- Accenture
- Start
- Feb 2012
- Primary completion
- Aug 2012
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of vestipitant in postoperative nausea and vomiting (PONV) (6 arms), sponsored by Accenture. Primary endpoint: Complete Response. Started Feb 2012; status: completed.
02
Drugs
vestipitant
03
Conditions
postoperative nausea and vomiting (PONV)
Beyond the preview
Go deeper on NCT01507194.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01507194.